Magnitude, Nature, and Risk Factors of Adverse Drug Reactions Associated with First Generation Antipsychotics in Outpatients with Schizophrenia: A Cross-Sectional Study

References

• Ayano G. First generation antipsychotics: pharmacokinetics, pharmacodynamics, therapeutic effects and side effects: a review. RRJChem. 2016;5(3):53–63.
   Google Scholar
• Abbott CC, Jaramillo A, Wilcox CE, Hamilton. DA. Antipsychotic drug effects in schizophrenia: a review of longitudinal FMRI investigations and neural interpretations. Curr Med Chem. 2013;20(3):428–437.23157635
   PubMed Web of Science ®Google Scholar
• The National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Children and Young People. Great Britain: The British Psychological Society and the Royal College of psychiatrists; 2013.
   Google Scholar
• Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61–68. doi:10.1002/wps.2069931922669
   PubMed Web of Science ®Google Scholar
• Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2014;41(3):656–663. doi:10.1093/schbul/sbu16425422511
   PubMed Web of Science ®Google Scholar
• Pierre C. How can the new antipsychotic medications improve quality of life in patients with schizophrenia? Expert Opin Pharmacother. 2016;17(13):1709–1711. doi:10.1080/14656566.2016.121543227447338
   PubMed Web of Science ®Google Scholar
• Haro JM, Novick D, Perrin E, Bertsch J, Knapp M. Symptomatic remission and patient quality of life in an observational study of schizophrenia: is there a relationship? Psychiatry Res. 2014;220(1–2):163–169. doi:10.1016/j.psychres.2014.07.03425194449
   PubMed Web of Science ®Google Scholar
• Chiang YL, Klainin‐Yobas P, Ignacio J, Chng CML. The impact of antipsychotic side effects on attitudes towards medication in people with schizophrenia and related disorders. J Clin Nurs. 2011;20(15–16):2172–2182. doi:10.1111/j.1365-2702.2010.03659.x21539628
   PubMed Web of Science ®Google Scholar
• DiBonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12(1):20. doi:10.1186/1471-244X-12-2022433036
   PubMed Web of Science ®Google Scholar
• Lucca JM, Varghese NA, Ramesh M, Ram D. Economic impact and severity of adverse drug reactions in patients with mental illness: a prospective observational study. Int J Health Allied Sci. 2017;6(2):93.
   Google Scholar
• Morrison P, Meehan T, Stomski NJ. Australian case managers’ views about the impact of antipsychotic medication on mental health consumers. Int J Ment Health Nurs. 2015;24(6):547–553. doi:10.1111/inm.1215426257312
   PubMed Web of Science ®Google Scholar
• Peluso MJ, Lewis SW, Barnes TR, Jones PB. Extrapyramidal motor side-effects of first-and second-generation antipsychotic drugs. Br J Psychiatry. 2012;200(5):387–392. doi:10.1192/bjp.bp.111.10148522442101
   PubMed Web of Science ®Google Scholar
• Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127–148. doi:10.1016/j.ncl.2010.10.00221172575
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41. doi:10.1016/S0140-6736(08)61764-X19058842
   PubMed Web of Science ®Google Scholar
• Pahari N, Tripathi SK, Maity T, Gupta BK, Bagchi C, Mondal DK. Evaluation and analysis of adverse drug reactions of second generation antipsychotics in a psychiatry out-patient department. Aggress Behav. 2012;6(6):59.
   Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. doi:10.1016/S0140-6736(13)60733-323810019
   PubMed Web of Science ®Google Scholar
• Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77. doi:10.1016/S2215-0366(19)30416-X31860457
   PubMed Web of Science ®Google Scholar
• Pakpoor J, Agius M. A review of the adverse side effects associated with antipsychotics as related to their efficacy. Psychiatr Danub. 2014;26(Suppl 1):273–284.25413553
   PubMedGoogle Scholar
• Kobylecki CJ, Jakobsen KD, Hansen T, Jakobsen IV, Rasmussen HB, Werge T. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology. 2009;59(4):222–226. doi:10.1159/00022373419521114
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P 450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5(1):6–13. doi:10.1038/sj.tpj.650028515492763
   PubMed Web of Science ®Google Scholar
• WHO. The World Health Report: 2001: Mental Health: New Understanding, New Hope. 2001: 1020–3311.
   Google Scholar
• Sridhar SB, Al-Thamer SSF, Jabbar R. Monitoring of adverse drug reactions in psychiatry outpatient department of a Secondary Care Hospital of Ras Al Khaimah, UAE. J Basic Clin Pharm. 2016;7(3):80. doi:10.4103/0976-0105.18326327330260
   PubMedGoogle Scholar
• Marder SR. Monitoring treatment and managing adherence in schizophrenia. J Clin Psychiatry. 2013;74(10):e21. doi:10.4088/JCP.12117tx2c24229761
   PubMedGoogle Scholar
• Day JC, Wood G, Dewey M, Bentall RP. A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients. Br J Psychiatry. 1995;166(5):650–653. doi:10.1192/bjp.166.5.6507620752
   PubMed Web of Science ®Google Scholar
• Briggs SR, Cheek JM. The role of factor analysis in the development and evaluation of personality scales. J Pers. 1986;54(1):106–148.
   Web of Science ®Google Scholar
• Sweileh WM, Odeh JB, Shraim NY, Sa’ed HZ, Sawalha AF, Al-Jabi SW. Evaluation of defined daily dose, percentage of British National Formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization. Saudi Pharm J. 2014;22(2):127–132. doi:10.1016/j.jsps.2013.03.00324648824
   PubMed Web of Science ®Google Scholar
• WHO. Requirements for Adverse Reaction Reporting. Geneva, Switzerland: World Health Organization; 1975.
   Google Scholar
• Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1(1):1–23.
   Web of Science ®Google Scholar
• Morrison P, Gaskill D, Meehan T, Lunney P, Lawrence G, Collings P. The use of the Liverpool University neuroleptic side‐effect rating scale (LUNSERS) in clinical practice. Aust N Z J Mental Health Nurs. 2000;9(4):166–176. doi:10.1046/j.1440-0979.2000.00181.x
   Google Scholar
• McCann TV, Clark E, Lu S. Subjective side effects of antipsychotics and medication adherence in people with schizophrenia. J Adv Nurs. 2009;65(3):534–543. doi:10.1111/j.1365-2648.2008.04906.x19222651
   PubMed Web of Science ®Google Scholar
• Day J, Kinderman P, Bentall R. A comparison of patients’ and prescribers’ beliefs about neuroleptic side‐effects: prevalence, distress and causation. Acta Psychiatr Scand. 1998;97(1):93–97. doi:10.1111/j.1600-0447.1998.tb09969.x9504710
   PubMed Web of Science ®Google Scholar
• Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1371–1376. doi:10.1136/bmj.321.7273.137111099280
   PubMed Web of Science ®Google Scholar
• Bollini P, Pampallona S, Orza M, Adams M, Chalmers T. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychol Med. 1994;24(2):307–316. doi:10.1017/S003329170002729X7916157
   PubMed Web of Science ®Google Scholar
• Taye H, Awoke T, Ebrahim J. Antipsychotic medication induced movement disorders: the case of Amanuel specialized mental hospital, Addis Ababa, Ethiopia. Am J Psychiatry Neurosci. 2014;2(5):76–82. doi:10.11648/j.ajpn.20140205.12
   Google Scholar
• Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527–542. doi:10.1517/14740338.2012.68352322563628
   PubMed Web of Science ®Google Scholar
• Igbinomwanhia NG, Olotu SO, James BO. Prevalence and correlates of antipsychotic polypharmacy among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria. Ther Adv Psychopharm. 2017;7(1):3–10. doi:10.1177/2045125316672134
   Web of Science ®Google Scholar
• Ling Young S, Taylor M, Lawrie SM. “First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2015.
   Web of Science ®Google Scholar
• Waterreus A, Morgan VA, Castle D, et al. Medication for psychosis–consumption and consequences: the second Australian national survey of psychosis. Aust N Z J Psychiatry. 2012;46(8):762–773. doi:10.1177/000486741245047122689337
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2009;36(1):94–103. doi:10.1093/schbul/sbp13019955388
   PubMed Web of Science ®Google Scholar
• Dudley K, Liu X, De Haan S. Chlorpromazine dose for people with schizophrenia. Cochrane Database Syst Rev. 2017;4.
   Google Scholar
• Wubeshet YS, Mohammed OS, Desse TA. Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel Mental Specialized Hospital, central Ethiopia: cross-sectional study. BMC Psychiatry. 2019;19(1):32. doi:10.1186/s12888-018-1999-x30658604
   PubMed Web of Science ®Google Scholar
• Miller MA. Gender-based differences in the toxicity of pharmaceuticals—the Food and Drug Administration’s perspective. Int J Toxicol. 2001;20(3):149–152. doi:10.1080/10915810131709772811488556
   PubMed Web of Science ®Google Scholar
• Zagaria MAE. Common adverse effects of antipsychotic agents in the elderly. US Pharm. 2010;35(11):22–26.
   Google Scholar